ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

FDA Grants Accelerated Approval to Imbruvica

November 29, 2013

Cancer Death Rates Declined 2.1 Percent Per Year.

October 19, 2007

More Than 450 Mammography Facilities Are Accredited By American College of Radiology

April 7, 1989

NCI Relates FDA Instructions On Latest IND Delays

October 29, 1976

Intermittent Androgen Deprivation Therapy Not Equal to Continuous Treatment, Study Finds

April 26, 2013

In Brief: Harmon Eyre Heads Medical Affairs, Research As Third Member OF ACS National Office “Troika”

April 16, 1993